An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features
- Authors
- Seo, H. -J.; Lee, B. C.; Seok, J. -H.; Jeon, H. J.; Paik, J. -W.; Kim, W.; Kwak, K. -P.; Han, C.; Lee, K. -U.; Pae, C. -U.
- Issue Date
- 9월-2013
- Publisher
- GEORG THIEME VERLAG KG
- Keywords
- response; remission; effectiveness; tolerability; atypical depression; bupropion XL
- Citation
- PHARMACOPSYCHIATRY, v.46, no.6, pp.221 - 226
- Indexed
- SCIE
SCOPUS
- Journal Title
- PHARMACOPSYCHIATRY
- Volume
- 46
- Number
- 6
- Start Page
- 221
- End Page
- 226
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/102237
- DOI
- 10.1055/s-0033-1353171
- ISSN
- 0176-3679
- Abstract
- Objectives: The present study aimed at investigating the effectiveness and tolerability of -bupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF). Methods: 51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression-Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as >= 50% reduction or <= 7 in SIGH-SAD total scores, respectively, at end of treatment. Results: The HAM-D-29 total score reduced by 55.3% from baseline (27.3 +/- 6.5) to end of treatment (12.2 +/- 6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5% from baseline (9.2 +/- 3.0) to end of treatment (4.2 +/- 2.8) (p<0.001). At the end of treatment, 24.4% (n=10) and 51.2% (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7%), dry mouth (11.8%), dizziness (9.8%), and dyspepsia (9.8%). Conclusions: Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.